UK Starting Salaries See Strongest Growth in 18 Months as Hiring Sentiment Improves 
Oil Prices Slip as U.S.-Iran Talks Ease Middle East Tensions 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Russian Stocks End Mixed as MOEX Index Closes Flat Amid Commodity Strength 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Vietnam’s Trade Surplus With US Jumps as Exports Surge and China Imports Hit Record 
Global Markets Slide as AI, Crypto, and Precious Metals Face Heightened Volatility 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
China Extends Gold Buying Streak as Reserves Surge Despite Volatile Prices 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Asian Currencies Stay Rangebound as Yen Firms on Intervention Talk 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
Moderna has assigned its new chief medical officer after recruiting a former Johnson & Johnson executive. It was reported that effective on July 6, Dr. Paul Burton will be joining the American pharmaceutical and biotechnology company based in Cambridge, Massachusetts.
As per Market Watch, Dr. Burton worked in Janssen Pharmaceuticals as its chief global medical affairs officer from March 2020, but he has been with Johnson & Johnson for 16 years and held various executive positions during his tenure.
Burton moves to Moderna
Dr. Paul Burton will be replacing Tal Zaks, who is said to be leaving Moderna after six years with the company. The incoming Moderna medical chief was also said to have previously worked as the vice president and head of cardiovascular and metabolic medical affairs in J&J.
He will be joining the biotech firm at the time when it is seeking approval from the government’s health regulators so that its COVID-19 vaccine could be used for adolescents too. Moderna’s chief executive officer, Stephane Bancel, said that testing results for the use of the vaccine in children will be available by fall. If the outcome is good, she said that it could help get a nod from the regulators and health safety boards.
“Paul’s extensive medical experience in the global pharmaceutical and biotech industry will be important to Moderna as we expand internationally and continue our journey as a commercial company,” CEO Bancel said in a press release. “As we work to deliver on the promise of mRNA science to create a new generation of transformative medicines for patients, Paul’s expertise across multiple therapeutic areas and his proven track record leveraging data science and digital technologies to reimagine medical engagement will be invaluable.”
Moderna’s foray into COVID-19 vaccine production
Moderna’s name became popular after joining the list of pharmaceutical firms that develop and produce vaccines for COVID-19. Its label was often in the headlines since last year, and now it is considered as one of the leading suppliers of vaccines worldwide.
Moderna’s CEO believes that with Dr. Paul Burton’s expertise, the company will achieve more of its goals in the coming years. She said that she is really looking forward to working with the new medical chief as they could achieve many things together.
